Martin Andres
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Benz R, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Feller A, Rauch D, Blum S, Mey U, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhaeusern R, Chalandon Y, Stussi G. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Adv 2020; 4:3699-3707.
Aug 11, 2020Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Aug 11, 2020Blood Adv 2020; 4:3699-3707
Benz Rudolf, O'Meara Stern Alix, Cantoni Nathan, Bargetzi Mario, Bianchi-Papina Elena, Rossi Davide, Passweg Jakob, Lohri Andreas, Berardi Simona, Feller Anita, Rauch Daniel, Blum Sabine, Mey Ulrich, Arn Kornelius, Andres Martin, Pabst Thomas, Baumann Michael, Novak Urban, Hitz Felicitas, Hess Urs, Zenhaeusern Reinhard, Chalandon Yves, Stussi Georg
Obinutuzumab in two patients suffering from immune-mediated thrombotic thrombocytopenic purpura intolerant to rituximab
Robertz J, Andres M, Mansouri Taleghani B, Koneth I, Binet F, Kremer Hovinga J. Obinutuzumab in two patients suffering from immune-mediated thrombotic thrombocytopenic purpura intolerant to rituximab. Am J Hematol 2019; 94:E259-E261.
Aug 9, 2019Obinutuzumab in two patients suffering from immune-mediated thrombotic thrombocytopenic purpura intolerant to rituximab
Aug 9, 2019Am J Hematol 2019; 94:E259-E261
Robertz Judith, Andres Martin, Mansouri Taleghani Behrouz, Koneth Irene, Binet Françoise-Isabelle, Kremer Hovinga Johanna A